Fisetin vs Urolithin A: Senolytic vs Mitophagy (2026)

Fisetin vs urolithin A: which has the stronger evidence?

Fisetin and urolithin A target different parts of cellular ageing. Fisetin is studied as a senolytic, with senescent-cell clearance demonstrated in selected preclinical models that have built up in tissue [1]. Urolithin A is a mitophagy inducer: it helps healthy cells recycle their damaged mitochondria [2].

Urolithin A has human studies of mitochondrial biomarkers and physical function, with important distinctions between primary and secondary endpoints. Fisetin's limited human findings are heterogeneous, and its proposed systemic senolytic effects remain unproven. No controlled human trial has shown that combining these supplements improves outcomes or has an established interaction profile. See our clinician's guide.

How do fisetin and urolithin A differ mechanistically?

Senescent cells stop dividing but don't die on schedule. They build up in tissue over decades and secrete inflammatory factors that damage neighbouring cells. Fisetin selectively pushes these senescent cells past their apoptotic threshold, clearing them and reducing the downstream inflammation [1]. This is a subtractive intervention — fewer damaged cells.

Mitophagy is the process by which cells identify and recycle damaged mitochondria. It declines with age, and restoring it is a leading strategy for preserving cellular energy production. Urolithin A is a gut-bacteria-derived metabolite of ellagitannins that was first shown to induce mitophagy, extend lifespan in C. elegans, and improve muscle function in aged mice and young rats [2]. This is a maintenance intervention — better upkeep of the mitochondria cells already have.

Senescence and mitochondrial maintenance are distinct areas of ageing research, but mechanistic differences do not establish that supplementing both compounds improves outcomes. No controlled human trial has shown that combining fisetin with urolithin A provides an additive benefit or is safe at high supplemental doses.

What does the human evidence show for urolithin A?

2026 evidence update: A systematic review published on 22 July 2026 included five randomized placebo-controlled urolithin A studies involving 236 participants with muscle-related outcomes. These five are defined by the review's inclusion criteria, not a count of all safety or pharmacokinetic studies [9].

The review could combine six-minute walking distance from only two trials. The pooled improvement versus placebo was 17.03 metres (95% CI −5.33 to 39.40; p=0.135). This was not statistically significant, and GRADE certainty was low. Other outcomes varied too much in population and measurement method to combine reliably.

Five muscle-related randomized trials in the 2026 review

Study	Population and intervention	Interpretation
Liu 2022 [4]	66 older adults; 1,000 mg/day for four months	Prespecified six-minute walking and maximal ATP production endpoints were not significantly better than placebo; some secondary muscle-endurance measures improved.
Singh 2022 [3]	88 untrained middle-aged adults; 500 or 1,000 mg/day for four months	Prespecified peak power was not significantly improved; selected secondary strength measures improved.
Zhao 2024 [9]	20 resistance-trained male athletes; 1,000 mg/day for eight weeks	Some strength and repetitions-to-fatigue measures improved; several other strength outcomes did not.
Whitfield 2025 [9]	42 male distance runners; 1,000 mg/day for four weeks	Results varied by exercise endpoint; no reproducible general muscle benefit can be inferred.
Monsalve Acevedo 2025 [9]	20 academy soccer players, mean age about 17.5; 1,000 mg/day for six weeks	Some exploratory performance differences; this athletic adolescent cohort cannot stand in for frail older adults.

These studies are clinically heterogeneous: two involved middle-aged or older adults; three involved trained or physically active male cohorts. A larger number of trials does not automatically mean a proven functional benefit [9].

The earlier first-in-human safety and pharmacokinetic study

Andreux 2019 randomized 60 healthy older adults to placebo or urolithin A doses of 250–1,000 mg for up to four weeks [6]. This study provides exposure, tolerability and exploratory mitochondrial biomarker evidence but did not test whether muscle-function endpoints improve. It should not be counted as one of the five trials in the 2026 review's muscle-outcome scope.

How to interpret positive secondary outcomes

The Liu and Singh trials reported some favorable secondary measures despite not meeting the relevant prespecified primary functional endpoints. The 2026 pooled walking estimate was directionally positive but its confidence interval included no benefit. The review's authors treated non-pooled muscle and mitochondrial findings as exploratory, rather than established clinical effects [9].

Funding and independence

The earlier Andreux, Singh and Liu publications involved Amazentis or authors affiliated with the commercial developer. The July 2026 review itself reported Korean government research funding and no declared commercial conflicts. The newer athletic studies have different populations and study contexts; funding for the three early trials must not be generalized automatically to every study in the five-trial review.

Fisetin's human evidence

Fisetin has registered studies and a small number of completed trials with results, but their doses, populations, endpoints and designs differ. Results from completed studies have been mixed and do not establish systemic senescent-cell clearance or clinical longevity benefits. The AFFIRM frailty trial remains unreported [5]. Preclinical muscle results support further research rather than an established clinical comparison [1].

How do the typical doses compare?

Aspect	Fisetin	Urolithin A
Mechanism	Candidate senolytic (preclinical clearance; human systemic clearance unproven)	Mitophagy inducer (recycles damaged mitochondria)
Typical daily dose	100–500 mg (continuous) or 20 mg/kg pulsed	500–1,000 mg daily, continuous
Dietary sources	Strawberries, apples, persimmons	Not present as such in food; produced by gut bacteria from pomegranate, walnuts, and berries
Bioavailability caveat	Poor absorption, low plasma peaks (unformulated)	Depends on gut-microbiota "producer" status when eaten as food; supplements bypass this
Peer-reviewed human RCT with a functional endpoint	Limited human findings; systemic senolytic benefit unproven	Five muscle-related RCTs met a July 2026 review's criteria (n=236); the two-trial pooled six-minute walk estimate was statistically inconclusive (low-certainty evidence)

Note that both compounds are dosed in the hundreds of milligrams, but urolithin A's commercial dose (500–1,000 mg) sits higher than fisetin's typical continuous range.

Is it safe to combine fisetin and urolithin A?

Safety, exposure and clinical outcomes for the concentrated fisetin–urolithin A combination remain untested in adequately controlled human studies. Their proposed mechanisms differ, but that is not proof of compatibility; the absence of published reports of an interaction also cannot establish safety.

Do not convert separate trial doses into a combined longevity protocol. People taking prescription medicines or managing medical conditions should review proposed supplement combinations with their clinician or pharmacist.

How do the evidence bases differ?

Urolithin A has randomised human trials measuring mitochondrial markers and several physical-function outcomes, although interpretation depends on the pre-specified endpoints and trial context. Fisetin has preclinical evidence for senolytic activity but has not demonstrated a validated clinical senolytic benefit in humans. Those different research questions can guide further reading; neither establishes that both compounds should be taken together.

Further reading: the distinct autophagy comparison with spermidine; the formulation and product-quality buying guide. Separate trials of each ingredient do not establish a beneficial or safe combination.

What we still don't know

Whether a larger, adequately powered trial in a clearly defined population will demonstrate a reproducible primary functional benefit from urolithin A. The July 2026 review's two-trial pooled six-minute walking result was statistically inconclusive, and its certainty was low [9].

Whether fisetin directly reduces systemic senescent-cell burden or improves clinically important ageing outcomes in people.

Whether a combined fisetin–urolithin A product improves outcomes or has acceptable interaction risks; neither a validated stack nor a comparative human RCT exists.

Bottom line

Urolithin A is studied for mitochondrial-related outcomes and has published human trials; fisetin is being investigated for senescence-related outcomes, with limited and heterogeneous human results. Neither has been shown to extend human lifespan, and a trial of each ingredient separately cannot justify a combined dosing plan. Clinical safety, interactions and additive benefit of concentrated fisetin plus urolithin A remain unestablished. See our clinician's guide, muscle and frailty review and senolytic evidence review.